Guardant Health, Inc. - GH STOCK NEWS

Guardant Health (Nasdaq: GH) has announced an expanded collaboration with Merck KGaA to advance precision oncology through its GuardantINFORM real-world evidence platform. This partnership aims to speed up therapy development for crucial cancer indications with high unmet needs. Data scientists from Guardant Health will work alongside Merck KGaA on various initiatives using genomic and clinical information from over 225,000 cancer patients. This collaboration emphasizes Guardant Health's commitment to improving patient outcomes and accelerating the availability of innovative cancer treatments.

Guardant Health, a precision oncology leader, will participate in the Morgan Stanley Global Healthcare Conference in New York City on September 12, at 8:10 a.m. ET. The event will include a fireside chat, accessible via a live and archived webcast on the company’s website. Guardant Health specializes in cancer diagnostics, leveraging proprietary tests like the Guardant360 and Guardant Reveal to enhance patient outcomes and reduce healthcare costs. Visit guardanthealth.com for more information.

Guardant Health Inc. (Nasdaq: GH) has expanded the availability of its innovative blood test, Guardant Reveal™, which detects minimal residual disease in colorectal, breast, and lung cancers without the need for a tissue biopsy. This test enables early identification of patients at higher risk for recurrence post-surgery, promising improved management of early-stage cancer. The Guardant Reveal test can be initiated three weeks post-surgery and outperforms traditional monitoring tools in predicting disease recurrence.

Guardant Health has received FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for patients with unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC). This test identifies patients who may benefit from the antibody drug conjugate ENHERTU. The Guardant360 CDx assay will enable oncologists to obtain comprehensive genomic results from a blood sample within a week, marking a significant advancement over traditional tissue biopsies. The HER2 mutations drive 2-4% of non-squamous NSCLC, representing a critical step for targeted cancer therapies.

Guardant Health (NASDAQ: GH) will participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference in Dana Point, CA. The management team is scheduled for a fireside chat on Wednesday, August 10, at 2:00 p.m. PT / 5:00 p.m. ET. Investors can access a live and archived webcast via the company's website. Guardant Health focuses on precision oncology, providing proprietary tests and analytics to improve cancer care. Its offerings include the Guardant360® suite for advanced cancer and the Shield™ test for cancer screening.

Guardant Health and Blueprint Medicines presented new data at the IASLC 2022 World Conference on Lung Cancer, revealing that the EGFR C797X mutation is a prevalent resistance mechanism to osimertinib for advanced non-small cell lung cancer (NSCLC) patients. The cumulative incidence of this mutation was found to be 12.5% after first-line treatment. The collaboration utilized the GuardantINFORM platform to analyze data from over 2,000 patients, emphasizing the need for next-generation EGFR inhibitors to combat C797X-driven resistance in NSCLC.

Guardant Health announced the presentation of studies at the IASLC 2022 World Conference on Lung Cancer in Vienna, focusing on its liquid biopsy tests' role in identifying treatment resistance mechanisms in lung cancer. Key findings will showcase the effectiveness of Guardant360, GuardantOMNI, and GuardantINFORM in advancing treatment strategies. Co-CEO Helmy Eltoukhy emphasized the significance of real-world data in improving patient outcomes. This event highlights Guardant Health's commitment to enhancing clinical decision-making in oncology.

Guardant Health reported Q2 2022 revenue of $109.1 million, marking a 19% increase from last year. Clinical and biopharma testing volumes surged by 40% and 65%, respectively. The company achieved Medicare coverage for Guardant Reveal™, enhancing access for colorectal cancer patients. Despite revenue growth, operating expenses rose 27% to $202.7 million, and net loss increased to $229.4 million. The firm expects 2022 revenue to reach $460 million to $470 million, indicating a 23% to 26% growth.

Guardant Health, Inc. (NASDAQ: GH) announced that its Guardant Reveal™ blood test for molecular residual disease (MRD) is now covered for fee-for-service Medicare patients in the US with stage II or III colorectal cancer (CRC). This coverage enables oncologists to detect circulating tumor DNA (ctDNA) in patients post-surgery, enhancing treatment decisions. The test marks a significant milestone as the first blood-only liquid biopsy for MRD testing in CRC. This decision complements existing Medicare coverage for other Guardant Health tests, boosting the company's position in precision oncology.